Denmark-based Scandion has two programs in clinical development with its compound SCO-101.

The most advanced program, CORIST, for the treatment of drug-resistant metastatic colorectal cancer, is a Phase II study. The second program, PANTAX, for the treatment of unresectable or metastatic pancreatic cancer, is a Phase Ib study.